



dedicated to finding a cure

FOR IMMEDIATE RELEASE

JDRF Applauds the Government of Saskatchewan for Enhancing Support for Individuals Living with Diabetes

TORONTO (December 14, 2011) – JDRF applauds the Government of Saskatchewan for following through on its commitment to provide additional support for individuals living with diabetes.

The Government of Saskatchewan announced effective immediately, two long-acting insulins, Lantus and Levemir, will be moved to open formulary and starting January 1st, 2012, the new Saskatchewan Insulin Pump Program will expand its coverage to include individuals living with type 1 diabetes 25 years of age and under.

“JDRF welcomes this announcement and commends the Government of Saskatchewan for taking the necessary steps to help ease the burden of diabetes on families in Saskatchewan,” said Andrew McKee, President and CEO of JDRF. “We thank the Government for its efforts as there has never been a greater need to cure, treat and prevent diabetes.”

Affecting 300,000 Canadians, type 1 diabetes can occur at any age, leaving children and adults dependent on injected or pumped insulin for life. The number of people living with type 1 diabetes is increasing by three to five per cent annually - the greatest rise being in children aged five to nine years.

“Diabetes continues to have an impact on millions of Canadians and their families,” says McKee. “Through initiatives such as these, we are making real progress in improving the lives of those living with type 1 diabetes. We look forward to working with the Government of Saskatchewan as we progress toward our goal of curing type 1 diabetes.”

About JDRF

JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is the largest charitable supporter of T1D research. The goal of JDRF is to improve the lives of every person affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal. Since its founding in 1970, JDRF has awarded more than \$1.5 billion to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. Past JDRF research efforts have helped to significantly improve the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered.

For more information, please visit www.jdrf.ca.

-30-

For More Information:

Jennifer Dent
National Director, Marketing and Communications
jdent@jdrf.ca
647-789-2025